ClinicalTrials.gg
CompletedNCT03383029Updated Jun 21, 2019

iEAT 2.0 Open Trial

An interventional study of iEAT Program in Gastrointestinal Disorders, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 12 Months to 6 Years. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
12 Months to 6 Years
Sex
All
01

Study summary

The purpose of this study is to learn more about the eating behaviors of children with chronic food refusal. Specifically, investigator's aim to see how the integrated Eating Aversion Treatment (iEAT) may affect a child's food consumption. The manual is a structured multidisciplinary treatment, including a psychologist and dietitian with consultation from a speech-language pathologist. The treatment is designed to increase the volume of foods a child eats and decrease their reliance on a feeding tube or formula. The manual includes informational handouts, data collection forms, and instructions to guide the increase in feeding demands while reducing reliance on formula to meet a child's nutritional needs.

Children with chronic food refusal will participate in this study at the Marcus Autism Center. All children who enroll will receive the iEAT treatment. This involves 10 bi-weekly sessions that last approximately one hour, over the course of 5 months and a 1 month follow-up visit. Therefore, the study will last a total of 6 months.

Read the detailed description

This study seeks to further the development of iEAT by including participants that demonstrated improvements in a previously conducted pilot study, and finalize the treatment manual to include the standardized decision rules to increase feeding demands, further integrate the multidisciplinary team (nutrition and speech pathology), and include supplementary sessions to better address individual treatment needs.

Investigators propose to enroll participants with chronic food refusal and formula or feeding tube dependence. Treatment will involve 10 biweekly outpatient appointments and 1 follow-up appointment of about 1 hour in length. Assessment and treatment will involve a multidisciplinary team including behavioral psychology, speech pathology and nutrition. Target behaviors including grams consumed, percent dependence on formula/feeding tube, and the clinical global impression scale, which will be assessed during a meal observation, 3-day food record, and evaluation with the dietitian and independent evaluator. Participants will be assessed pre-treatment, mid-treatment, and post-treatment and complete a one month follow-up to assess long term effects.

02

Conditions studied

  • Gastrointestinal Disorders

Keywords

  • Nutrition
  • Behavioral
03

In context

Gastrointestinal Diseases

548 studies on the registry are indexed under Gastrointestinal Diseases; 101 are open to participants now.

This study's enrollment of 15 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

Emory University is the lead sponsor of 1,405 studies on the registry; 225 are open to participants now.

Of its 237 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with partial food refusal as evidenced by greater than 75% of caloric needs met by bottle, formula, or tube feedings
  • Have a medical history significant for an organic factor (e.g., gastrointestinal issues) which influenced the development of feeding concern
  • Safe to consume up to 100% of his/her needs orally
  • Parents of subjects must be English literate
  • Ability to complete at least 2 structured meals each day

Exclusion criteria

Exclusion Criteria:

  • Active medical diagnoses requiring hospitalization or significant oversight from a physician
  • Active medical, structural, or functional limitations preventing safe oral intake of pureed foods
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    iEAT

    Children with food refusal will participate in the iEAT program.

    Behavioral: iEAT Program

Interventions

  • BehavioraliEAT Program

    The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.

06

What researchers measure

Primary outcomes

  1. Change in Percent Oral Intake

    Oral intake will be assessed through the three-day food diary on which parents will record the child's daily intake. The percent of needs consumed orally will be reported.

    Time frame: Baseline, Post-Intervention (Week 20)

  2. Change in Total Oral Grams Consumed During Meal

    Total oral grams consumed during a meal will be rated by trained observers captured by the meal observation form and collected during study visits.

    Time frame: Baseline, Post-Intervention (Week 20)

  3. Change in Percent Needs Met by Formula or Feeding Tube

    Formula and feeding tube intake will be assessed through the three-day food diary on which parents will record the child's daily intake. The percent of needs consumed via bottle or tube will be reported.

    Time frame: Baseline, Post-Intervention (Week 20)

  4. Clinical Global Impression Scale - Improvement (CGI-I) Score

    The CGI-I is a seven-point scale measure of overall change from baseline. Scores will be ranked from 1 (Very Much Improved) through 4 (Unchanged) to 7 (Very Much Worse). Scores of "Much Improved" or "Very Much Improved" will be used to define positive responses; all other scores will indicate negative responses. Total scores range from 1 to 7; where 1 indicates the most improvement and 7 indicates greatest worsening.

    Time frame: Post-Intervention (Week 20)

Secondary outcomes

  1. Change in Parenting Stress Index (PSI) Score

    The PSI is a 36-item measure completed by a parent or caregiver designed to screen for stress in the parent-child relationship, identifying dysfunctional parenting and child adjustment problems. Raw scores are converted into percentile scores. A score which falls between the 15th and 80th percentile is considered typical. High scores are those at or above the 85th percentile.

    Time frame: Baseline, Post-Intervention (Week 20)

07

Study locations

1 site
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2019, 16 months.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's 16 months is below that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 26, 2017
StartActual
Nov 29, 2017
Primary completionActual
Apr 25, 2019
CompletionActual
Apr 25, 2019
Last update
Jun 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03383029
Lead sponsor
Emory University
Responsible party
Lindsey Burrell (Assistant Professor, Emory University) — Principal investigator
First posted
Dec 26, 2017
Start date
Nov 29, 2017
Primary completion
Apr 25, 2019
Completion
Apr 25, 2019
Last update
Jun 21, 2019

Study contacts

Lindsey Burrell, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion